Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Shenhong G. Wu

Oncology
Stony Brook Medicine
Stony Brook Internists University Faculty Practice Corporation
3 Edmond D Pellegrino Rd, 
Stony Brook, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth

Distinguished in WT1-Related Wilms Tumor Syndromes
Stony Brook Medicine
Stony Brook Internists University Faculty Practice Corporation
3 Edmond D Pellegrino Rd, 
Stony Brook, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Shenhong Wu is an Oncologist in Stony Brook, New York. Dr. Wu is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma.

His clinical research consists of co-authoring 52 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
Suny/stony Brook University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

STONY BROOK INTERNISTS UNIVERSITY FACULTY PRACTICE CORPORATION
3 Edmond D Pellegrino Rd, Stony Brook, NY 11794
Call: 631-638-1000
Other Locations
STONY BROOK INTERNISTS UNIVERSITY FACULTY PRACTICE CORPORATION
26 Research Way, East Setauket, NY 11733
Call: 631-444-0580

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: a Randomized Phase 3 Non-Inferiority Trial (IMAGINE)
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
View 4 Less Clinical Trials

53 Total Publications

Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.
Increased Risk of Hyperglycemia in Advanced Urothelial Cancer Patients Treated with Enfortumab Vedotin: A Systematic Review and Meta-Analysis.
Journal: Cancer investigation
Published: May 13, 2025
View All 53 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert J. Motzer
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Robert J. Motzer
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (45.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Motzer is an Oncologist in New York, New York. Dr. Motzer is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Teratoma of the Mediastinum, Nephrectomy, and Orchiectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Chung-han H. Lee
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Chung-han H. Lee
Oncology
500 Westchester Ave, 
West Harrison, NY 
 (33.3 miles away)
646-422-4545
Languages Spoken:
English
See accepted insurances

Chung-han Lee is an Oncologist in West Harrison, New York. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Renal Cell Carcinoma (RCC), and Familial Wilms Tumor 2.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Martin H. Voss
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Martin H. Voss
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (45.0 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Martin Voss is an Oncologist in New York, New York. Dr. Voss is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wu's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Wu is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Wu is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Wu is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Prostate Cancer
      Dr. Wu is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Muscle Invasive Bladder Cancer
      Dr. Wu is
      Distinguished
      . Learn about Muscle Invasive Bladder Cancer.
      See more Muscle Invasive Bladder Cancer experts
    • Non-Muscle Invasive Bladder Cancer
      Dr. Wu is
      Distinguished
      . Learn about Non-Muscle Invasive Bladder Cancer.
      See more Non-Muscle Invasive Bladder Cancer experts
    View All 9 Distinguished Conditions
    • Advanced
    • Bladder Cancer
      Dr. Wu is
      Advanced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Choriocarcinoma
      Dr. Wu is
      Advanced
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    • Familial Wilms Tumor 2
      Dr. Wu is
      Advanced
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    • Laryngeal Cancer
      Dr. Wu is
      Advanced
      . Learn about Laryngeal Cancer.
      See more Laryngeal Cancer experts
    • Upper Tract Urothelial Carcinoma (UTUC)
      Dr. Wu is
      Advanced
      . Learn about Upper Tract Urothelial Carcinoma (UTUC).
      See more Upper Tract Urothelial Carcinoma (UTUC) experts
    • Urothelial Cancer
      Dr. Wu is
      Advanced
      . Learn about Urothelial Cancer.
      See more Urothelial Cancer experts
    View All 7 Advanced Conditions
    • Experienced
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Wu is
      Experienced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Desmoplastic Small Round Cell Tumor
      Dr. Wu is
      Experienced
      . Learn about Desmoplastic Small Round Cell Tumor.
      See more Desmoplastic Small Round Cell Tumor experts
    • Familial Pancreatic Cancer
      Dr. Wu is
      Experienced
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Liver Cancer
      Dr. Wu is
      Experienced
      . Learn about Liver Cancer.
      See more Liver Cancer experts
    • Lymphofollicular Hyperplasia
      Dr. Wu is
      Experienced
      . Learn about Lymphofollicular Hyperplasia.
      See more Lymphofollicular Hyperplasia experts
    • Lymphoid Hyperplasia
      Dr. Wu is
      Experienced
      . Learn about Lymphoid Hyperplasia.
      See more Lymphoid Hyperplasia experts
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved